Related Experiment Video
Updated: Sep 8, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
What Antiepileptics Have the Highest Risk of Parkinsonism? A Disproportionality Analysis in the World Health
1Emeritus Professor of Medical and Clinical Pharmacology, Toulouse, France.
Background:
The present study was performed to investigate which antiepileptic drug (AED) has the highest risk of drug-induced parkinsonism (DIP).
Objective:
The aim was to evaluate associations between AEDs and DIP reports in the World Health Organization pharmacovigilance database, Vigibase.
Methods:
Individual case safety reports (ICSRs) in patients ≥45 years registered between January 1, 2000 and June 31, 2024 with carbamazepine, lamotrigine, levetiracetam, or sodium valproate as "Parkinson-like events" (PLE) were extracted. Disproportionality analyses were performed, with cases being PLE and non-cases all other ICSRs. Results are shown as reporting odds ratios (ROR).
Results:
Among 16,174,796 ICSRs, 3339 reported PLE with the four AEDs, mainly in females between 45 and 64 years. The highest ROR value was with valproate sodium (3.09 [2.01-3.29]), followed by lamotrigine (2.14 [2.01-2.28]), levetiracetam (1.43 [1.32-1.55]), and carbamazepine (1.09 [1.01-1.17]). DIP risk increased with the number of associated AEDs.
Conclusions:
Among AEDs, valproate sodium is associated with the higher risk of PLE and carbamazepine with the lowest.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Parkinson's Disease: Overview
Antiepileptic Drugs: Glutamate Antagonists

